GPR132 and acute myeloid leukemia: Considering the chemical skeleton differences distinguishing 8GL and other reported in vitro GPR132 agonizts, as well as it is in vivo safety and efficiency in AML models, our results support a rationale for exploiting more potent and specific GPR132-targeted 8GL derivatives for the treatment of different types of AML.